DSG's EDC to be Used by Biotech Co. for Chronic Kidney Disease

February 1, 2010

Company News Release

MALVERN, Pa., Jan. 29, 2010 —DSG‘s eCaseLink™ Electronic Data Capture (EDC) and data management are currently being used by a biotechnology company for two current Phase II and Phase IIa clinical trials for treatments of progressive and chronic kidney disease. The company uses DSG’s eCaseLink™ to automate and manage the data collection process during the clinical trial lifecycle. In addition, DSG combines data management services with eCaseLink™ to seamlessly optimize data collection and analysis.

The Phase II study, is a new treatment that may help people in the early stage of diabetic nephropathy, a progressive kidney disease. The second study, currently in Phase IIa, is a treatment for anemia in chronic kidney disease. The two clinical trials demand a data capture and management solution that speeds time-to-market while complying with all appropriate regulatory procedures. “Partnering with innovative drug companies like this, helping to find ways to help those suffering from progressive and chronic kidney disease, is an ideal way for DSG’s unique eCaseLink™ EDC system to be employed in clinical trials,” said Tony Varano, CEO of DSG.

Related Content:

News